class="">Eight companies went public in the year’s most active week. Three priced above the range and each finished above its IPO price (average return of 38%). Biotech Novan and ad-tech platform The Trade Desk led the group with a 67% and 65% first da...read more
AC Immune, a Swiss biotech developing therapies for Alzheimer's, partnered with Genentech, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. AC Immune plans to list on the Nasdaq under the symbol ACIU. Credit...read more
class="">Nine deals are on the IPO calendar for the week ahead, aiming to raise a combined $1.2 billion. Set to be the most active week of 2016, the wave of deals counts three founder-led high-growth software companies and a teleco...read more
AC Immune, which is a Swiss biotech developing therapies for Alzheimer's disease, announced terms for its IPO on Tuesday. The Lausanne, Switzerland-based company plans to raise $55 million by offering 4.5 million shares at a price range of $11 to $13....read more
US IPO Weekly Recap: 8 offerings average 38% returns in year's busiest week for IPOs
class="">Eight companies went public in the year’s most active week. Three priced above the range and each finished above its IPO price (average return of 38%). Biotech Novan and ad-tech platform The Trade Desk led the group with a 67% and 65% first da...read more
AC Immune prices IPO at $11, the low end of the range
AC Immune, a Swiss biotech developing therapies for Alzheimer's, partnered with Genentech, raised $66 million by offering 6 million shares at $11, the low end of the range of $11 to $13. AC Immune plans to list on the Nasdaq under the symbol ACIU. Credit...read more
US IPO Week Ahead: Year's most active week with 9 IPOs
class="">Nine deals are on the IPO calendar for the week ahead, aiming to raise a combined $1.2 billion. Set to be the most active week of 2016, the wave of deals counts three founder-led high-growth software companies and a teleco...read more
Alzheimers biotech AC Immune sets terms for $55 million IPO
AC Immune, which is a Swiss biotech developing therapies for Alzheimer's disease, announced terms for its IPO on Tuesday. The Lausanne, Switzerland-based company plans to raise $55 million by offering 4.5 million shares at a price range of $11 to $13....read more